May 18th 2024
Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Study: Children With SCD Not Found to Abuse Opioids Long-Term
April 10th 2024A retrospective cohort study assessed patterns of opioid use in children with sickle cell disease (SCD) following their initial opioid prescription for pain management, finding that concerning patterns of opioid abuse did not develop.
Read More
Dr Robert Sidbury on Implementing Value-Based Care Initiatives in a Pediatric Dermatology Practice
April 9th 2024Robert Sidbury, MD, MPH, FAAD, division head of dermatology at Seattle Children's Hospital and professor of pediatrics at the University of Washington School of Medicine, discusses implementing value-based care initiatives in a pediatric dermatology practice.
Watch
Institutional Practices for Charitable Medication Access for Uninsured Patients
Analysis of a patient sample enrolled in charitable care at an academic medical center revealed that chronic medications were variably filled at a significant cost.
Read More
In AML, CAR T-Cell Therapy Has Higher CR Rate After Transplant
April 8th 2024In this investigation, investigators sought insights into the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy in acute myeloid leukemia (AML), with a particular focus on how various patient subgroups fared for complete remission (CR).
Read More
Health Equity and Access Weekly Roundup: April 8, 2024
April 8th 2024The Center on Health Equity and Access covered the burden faced by caregivers, transgender health care, pre-exposure prophylaxis uptake, disparities in postpartum mental health care, and cost-related medication nonadherence among patients with chronic obstructive pulmonary disease.
Read More
FDA Approves Cilta-Cel for Earlier Treatment of RRMM
April 6th 2024Most recently, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend ciltacabtagene autoleucel (Carvykti; Johnson & Johnson) in patients who have received at least 1 line of treatment for relapsed/refractory multiple myeloma (RRMM).
Read More
Kathy Oubre on Navigating the Aftermath of the Change Healthcare Cyberattack
April 5th 2024Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, is 1 of 6 cochairs for the 2024 Community Oncology Conference, and here she discusses how meeting content has incorporated ongoing coverage of the extremely disruptive cyberattack and how there is still so much work to be done.
Watch
Jon Levitt Highlights Urgency for Stronger Employer Oversight of PBMs
April 5th 2024Jonathan E. Levitt, Esq, founding partner of boutique health care law firm Frier Levitt, LLC, discusses a recent class-action lawsuit brought against Johnson & Johnson in which an employee alleged a breach of fiduciary duty regarding her employer-sponsored pharmacy benefits.
Watch
Trends in Low-Value Cancer Care During the COVID-19 Pandemic
Among adults with newly diagnosed cancer, rates of low-value cancer services persisted throughout the COVID-19 pandemic in areas ranging from peridiagnosis imaging to end-of-life care.
Read More
Dr Sandra Stein on the Important Issue of Social Determinants of Health
April 5th 2024After moderating the panel discussion at The American Journal of Managed Care®’s Institute for Value-Based Medicine® (IVBM) event held in partnership with Banner|Aetna, Sandra Stein, MD, chief medical officer of Banner Health Plans, shared her key takeaway.
Watch
The newest treatment approved for amyotrophic lateral sclerosis (ALS) will be withdrawn from the market due to negative clinical trial results; former President Trump’s surgeon general is advocating for conservative states to support needle exchanges; new US hepatitis C infections dropped slightly in 2022 after more than a decade of steady increases.
Read More
Accountable Care Organization Initiatives to Improve the Cost and Outcomes of Specialty Care
April 2nd 2024Engaging specialty physicians is an emerging area of focus for Medicare accountable care organizations. Enhanced data on specialist costs and outcomes are essential to addressing alignment challenges.
Read More